Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Avita Medical Ltd. (OTC: AVMXY).

Full DD Report for AVMXY

You must become a subscriber to view this report.


Recent News from (OTC: AVMXY)

AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch
AVITA Medical (ASX: AVH , OTCQX: AVMXY ) today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California. Effective July 1, 2018, AVITA Medical acquired the facility from a Fortune 500...
Source: Business Wire
Date: August, 22 2018 23:21
AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference
Results from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium AVITA Medical (ASX: AVH , OTCQX: AVMXY ) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clin...
Source: Business Wire
Date: August, 22 2018 00:35
Avita Medical: RECELL Spray-On-Skin Nears FDA Approval
Avita Medical ( AVMXY ) is a skin regenerative medicine company based in California with operations in Europe and Australia that is nearing potential FDA approval for its RECELL spray-on-skin device to improve the treatment of burn victims. RECELL is designed as a point-of-care device with a 3...
Source: SeekingAlpha
Date: August, 16 2018 14:17
AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns
FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers AVITA Medical (ASX: AVH , OTCQX: AVMXY ) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the U....
Source: Business Wire
Date: August, 09 2018 00:26
AVITA Medical Announces Results of Extraordinary General Meeting
AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, announced that both resolutions presented to shareholders were approved at an Extraordinary Gene...
Source: Business Wire
Date: July, 23 2018 16:54
AVITA Medical Announces Expansion of Management Team to Support Planned U.S. Launch of RECELL® Device
AVITA Medical (ASX: AVH ) (OTCQX: AVMXY ) today announced that it expanded its management team in the commercial, legal and medical affairs functions to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns. Joining AVITA Medical ar...
Source: Business Wire
Date: July, 19 2018 20:37
AVITA Medical Announces Acquisition of Manufacturing Facility to Support Planned U.S. Launch of RECELL® Device
AVITA Medical (ASX: AVH , OTCQX: AVMXY ) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns. The facility is currently operated by a For...
Source: Business Wire
Date: June, 27 2018 19:50
AVITA Medical Announces Presentation of RECELL® Device Clinical Trial Results at Changhai Academic Week for Burns Treatment Conference in China
Also announces that Plastic Surgery Department of Peking Union Medical College Hospital (PUMCH) completes first national training session in treatment of vitiligo and scars AVITA Medical (ASX: AVH , OTCQX: AVMXY ) announced today that results from two U.S. pivotal clinical trials...
Source: Business Wire
Date: June, 26 2018 20:33
AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns Published in Journal of Burn Care & Research
Trial demonstrated statistically significant reduction in donor skin requirements and pain, increased patient satisfaction, and improved donor scar outcomes AVITA Medical (ASX: AVH , OTCQX: AVMXY ) announced today that results from a pivotal clinical trial demonstrating the effect...
Source: Business Wire
Date: June, 25 2018 20:11
What Will Vericel Do With The Money? Clues From The Jefferies Conference
Since quintupling Epicel's commercialization in 2016 and rolling out MACI a year later, Vericel Corporation ( VCEL ) has been a fast-growing but relatively boring expansion story. Sales growing +30% year-to-year over the last four quarters, margins improving, products gaining market share, sto...
Source: SeekingAlpha
Date: June, 20 2018 13:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-101.1651.181.181.1632,322
2018-12-071.181.151.201.15118,245
2018-12-061.231.191.251.1868,166
2018-12-051.221.221.311.20190,146
2018-12-041.221.221.311.20190,146

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-105,40032,32216.7069Cover
2018-12-075,200118,2454.3976Cover
2018-12-0625,20364,54139.0496Short
2018-12-0435,200145,14624.2514Cover
2018-11-2919,56262,01731.5430Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVMXY.


About Avita Medical Ltd. (OTC: AVMXY)

Logo for Avita Medical Ltd. (OTC: AVMXY)

Avita Medical s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension RES , an autologous suspension comprised of the patients own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated. In all countries outside of Europe, our portfolio is marketed under the ReCell brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. ReCell is TGA registered in Australia, and CFDA cleared in China. In the United States, ReCell is an investigational device limited by federal law to investigational use. In Europe, our portfolio of medical device products received CE mark approval as three tailored product presentations, with three individual brand names. ReCell is designed for the treatment of burns and plastic reconstructive procedures ReGenerCell has been formulated for chronic wounds including leg and foot ulcers and ReNovaCell is tailored for aesthetic applications including the restoration of pigmentation.

 

 

 

Current Management

  • Michael Perry / CEO, Executive Director
  • Dale Sander / CFO
  • Timothy Rooney / Chief Admin. Officer
  • Lou Panaccio / Chairman
  • Louis Drapeau / NonExecutive Director
  • Suzanne Crowe / NonExecutive Director
  • Jeremy Curnock Cook / NonExecutive Director

Current Share Structure

  • Market Cap: $32,987,773 - 03/15/2018
  • Authorized: 838,989,992 - 08/30/2016
  • Issue and Outstanding: 673,219,854 - 12/31/2016

 


Recent Filings from (OTC: AVMXY)

Semi-Annual Report - Half Yearly Reports and Accounts
Filing Type: Semi-Annual Report - Half Yearly Reports and AccountsFiling Source: OTC Markets
Filing Date: February, 27 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 30 2018
Annual Report - Avita Releases Annual Report to Shareholders
Filing Type: Annual Report - Avita Releases Annual Report to ShareholdersFiling Source: OTC Markets
Filing Date: October, 31 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: October, 30 2017
Annual Report - Avita Medical Limited Full Financial Report
Filing Type: Annual Report - Avita Medical Limited Full Financial ReportFiling Source: OTC Markets
Filing Date: September, 29 2017

 

 


Daily Technical Chart for (OTC: AVMXY)

Daily Technical Chart for (OTC: AVMXY)


Stay tuned for daily updates and more on (OTC: AVMXY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AVMXY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVMXY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AVMXY and does not buy, sell, or trade any shares of AVMXY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/